CLDX Stock Recent News

CLDX LATEST HEADLINES

CLDX Stock News Image - Zacks Investment Research

The consensus price target hints at a 67.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research 2024 May 09
CLDX Stock News Image - Zacks Investment Research

The heavy selling pressure might have exhausted for Celldex (CLDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research 2024 Apr 09
CLDX Stock News Image - Zacks Investment Research

Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research 2024 Apr 08
CLDX Stock News Image - GlobeNewsWire

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Inflammation & Immunology Corporate Panel Discussion” at TD Cowen's 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024 from 2:10 to 3:10 PM ET.

GlobeNewsWire 2024 Mar 05
CLDX Stock News Image - Zacks Investment Research

Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research 2024 Feb 29
CLDX Stock News Image - Zacks Investment Research

The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in Celldex (CLDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research 2024 Feb 29
CLDX Stock News Image - Zacks Investment Research

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.56 per share a year ago.

Zacks Investment Research 2024 Feb 26
CLDX Stock News Image - Seeking Alpha

MoneyShow's Best Investment Ideas For 2024: Part 3

Seeking Alpha 2024 Jan 29
CLDX Stock News Image - GlobeNewsWire

HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28th at 5:05 pm ET. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.

GlobeNewsWire 2023 Nov 27
CLDX Stock News Image - InvestorPlace

The article embarks on a transformative journey through the biotech frontier, where the listed companies stand as titans reshaping healthcare norms. The first one's strategic collaboration with a multinational healthcare giant propels financial strength, unlocking accelerated milestones in key programs.

InvestorPlace 2023 Nov 17
10 of 31